Antidiabetic drugs, glycemic control and risk of benign prostatic hyperplasia

被引:2
作者
Nygard, Lotta H. [1 ]
Talala, Kirsi [2 ]
Taari, Kimmo [3 ,4 ]
Tammela, Teuvo L. J. [1 ,5 ]
Auvinen, Anssi [6 ]
Murtola, Teemu J. [1 ,5 ]
机构
[1] Univ Tampere, Fac Med & Hlth Technol, Unit Med, Tampere, Finland
[2] Finnish Canc Registry, Canc Soc Finland, Mass Screening Registry, Helsinki, Finland
[3] Univ Helsinki, Dept Urol, Helsinki, Finland
[4] Helsinki Univ Hosp, Helsinki, Finland
[5] Tampere Univ Hosp, Dept Urol, Tampere, Finland
[6] Univ Tampere, Fac Social Sci, Unit Hlth Sci, Tampere, Finland
关键词
antidiabetic drugs; benign prostatic hyperplasia; blood glucose; cohort; risk; URINARY-TRACT SYMPTOMS; METABOLIC SYNDROME; INFLAMMATION; INSULIN; ASSOCIATION; GLUCOSE; PROGRESSION; MEDIATORS;
D O I
10.1002/pros.24456
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Diabetes has been associated with an increased risk of benign prostatic hyperplasia (BPH). However, the role of antidiabetic drugs as a BPH risk factor is unclear. The objective of our study was to examine the risk of BPH by antidiabetic drug use and glycemic control in a large population-based cohort of Finnish men. Methods A total of 74,754 men in the Finnish Randomized Study of Screening for Prostate Cancer (FinRSPC) free of BPH at baseline in 1996-1999 were linked to the national medication reimbursement database for information on physician-prescribed antidiabetic drug purchases. Information on recorded BPH procedures and diagnoses was obtained from the National Care Register for Health Care, and for a subgroup of 17,739 men, information on blood glucose levels (BGLs) from the Fimlab Laboratories database. Cox regression with antidiabetic drug use and BGL as time-dependent variables was used to analyze the risks for starting BPH medication, recorded BPH diagnosis, and undergoing BPH surgery. The analysis was adjusted for age, use of statins, antihypertensive medication, and nonsteroidal anti-inflammatory drugs. Results Of the subjects, 14,012 men (18.7%) used antidiabetic medication. Of the subgroup with fasting blood glucose data available, 7487 (42.2%) had diabetic level. The risks for BPH diagnosis (HR: 1.08, 95% CI: 1.03-1.13) and surgery (HR: 1.16, 95% CI: 1.09-1.24) were slightly elevated among antidiabetic drug users compared to nonusers. The association was strongest for insulin use. Similarly, risk of BPH surgery was increased in men with diabetic blood glucose compared to normoglycemic men. The risk association was attenuated by use of antidiabetic drugs. Conclusions Diabetic BGL and antidiabetic medication use, especially insulin, are associated with an elevated risk of BPH surgery compared to nondiabetic men. These findings support the roles of insulin use and untreated hyperglycemia as possible BPH risk factors.
引用
收藏
页码:246 / 258
页数:13
相关论文
共 32 条
[1]   Peptide growth factors in the prostate as mediators of stromal epithelial interaction [J].
Byrne, RL ;
Leung, H ;
Neal, DE .
BRITISH JOURNAL OF UROLOGY, 1996, 77 (05) :627-633
[2]  
Chen Z, 2015, INT J CLIN EXP MED, V8, P11289
[3]   Inflammatory mediators in the development and progression of benign prostatic hyperplasia [J].
De Nunzio, Cosimo ;
Presicce, Fabrizio ;
Tubaro, Andrea .
NATURE REVIEWS UROLOGY, 2016, 13 (10) :613-626
[4]   Association between severity of lower urinary tract symptoms, erectile dysfunction and metabolic syndrome [J].
Demir, Omer ;
Akgul, Korhan ;
Akar, Zafer ;
Cakmak, Ozgur ;
Ozdemir, Ismail ;
Bolukbasi, Ahmet ;
Can, Ertan ;
Gumus, Bilal H. .
AGING MALE, 2009, 12 (01) :29-34
[5]   Distribution of inflammation, pre-malignant lesions, incidental carcinoma in histologically confirmed benign prostatic hyperplasia: A retrospective analysis [J].
Di Silverio, F ;
Gentile, V ;
De Matteis, A ;
Mariotti, G ;
Giuseppe, V ;
Luigi, PA ;
Sciarra, A .
EUROPEAN UROLOGY, 2003, 43 (02) :164-175
[6]  
Dobrek Lukasz, 2015, Pol Merkur Lekarski, V39, P263
[7]  
Fimlab Laboratoriot Oy Ltd, BRIEFL ENGL
[8]  
Fitzpatrick JM, 2006, BJU INT, V97, pI, DOI 10.1111/j.1464-410X.2006.06097.x
[9]   Metabolic syndrome and lower urinary tract symptoms: the role of inflammation [J].
Gacci, M. ;
Vignozzi, L. ;
Sebastianelli, A. ;
Salvi, M. ;
Giannessi, C. ;
De Nunzio, C. ;
Tubaro, A. ;
Corona, G. ;
Rastrelli, G. ;
Santi, R. ;
Nesi, G. ;
Serni, S. ;
Carini, M. ;
Maggi, M. .
PROSTATE CANCER AND PROSTATIC DISEASES, 2013, 16 (01) :100-105
[10]   Metabolic syndrome and benign prostatic enlargement: a systematic review and meta-analysis [J].
Gacci, Mauro ;
Corona, Giovanni ;
Vignozzi, Linda ;
Salvi, Matteo ;
Serni, Sergio ;
De Nunzio, Cosimo ;
Tubaro, Andrea ;
Oelke, Matthias ;
Carini, Marco ;
Maggi, Mario .
BJU INTERNATIONAL, 2015, 115 (01) :24-31